CRNX Crinetics Pharmaceuticals

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX), today announced that company management will participate in two upcoming investment bank conferences. The TD Cowen 45th Annual Healthcare Conference is being held in Boston, MA, and the Leerink Global Healthcare Conference is taking place in Miami, FL.

TD Cowen 45th Annual Healthcare Conference

          Fireside chat on Monday, March 3, 2025 at 11:10 a.m. Eastern Time

          Webcast link

Leerink Global Healthcare Conference

          Fireside chat on Monday, March 10, 2025 at 4:20 p.m. Eastern Time

          Webcast link

The live and archived webcasts will be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at .

If you are interested in arranging a 1x1 meeting with management, please contact your conference representative.

ABOUT CRINETICS PHARMACEUTICALS

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational, first-in-class, oral ACTH antagonist, that is currently in development for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.

Investors:

Gayathri Diwakar

Head of Investor Relations



(858) 345-6340

Media:

Natalie Badillo

Head of Corporate Communications



(858) 345-6075



EN
20/02/2025

Underlying

CRNXCrinetics Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Crinetics Pharmaceuticals

 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Of...

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CRNX), today announced the appointment of Tobin “Toby” Schilke as chief financial officer, effective February 28, 2025. Mr. Schilke is a seasoned biopharma executive with over 25 years of global pharmaceutical experience. In prior roles, his leadership was instrumental in transforming several biotech companies from R&D-focused entities into fully integrated commercial organizations. “I am excited to welcome Toby to our senior leadership team during this trans...

9h / 59m 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investo...

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX), today announced that company management will participate in two upcoming investment bank conferences. The TD Cowen 45th Annual Healthcare Conference is being held in Boston, MA, and the Leerink Global Healthcare Conference is taking place in Miami, FL. TD Cowen 45th Annual Healthcare Conference          Fireside chat on Monday, March 3, 2025 at 11:10 a.m. Eastern Time          Webcast link Leerink Global Healthcare Conference           Firesi...

February 20, 2025 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Un...

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 105,100 shares of its common stock and granted an aggregate of 9,950 restricted stock unit (“RSU”) awards to 14 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Induce...

February 10, 2025 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 ...

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, February 27 @ 4:30 p.m. ET Domestic:         1-800-267-6316International:    1-203-518-9783Conference ID:  CRNXQ4 Webc...

February 6, 2025 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Und...

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 96,100 shares of its common stock to sixteen new non-executive employees and 100,000 to one new executive employee under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted...

January 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch